Loading...
•
Sep 30, 2020
Glaukos Q3 2020 Earnings Report
Glaukos' third quarter performance reflected the company's commitment to strategic priorities amidst COVID-19 challenges.
Key Takeaways
Glaukos Corporation reported an 11% increase in net sales for the third quarter of 2020, reaching $64.8 million compared to $58.5 million in the same period of 2019. The company's gross margin was approximately 72%, with a non-GAAP gross margin of approximately 85%. Operating expenses were $59.3 million, and the net loss was $15.7 million, or ($0.35) per diluted share.
Net sales reached $64.8 million in Q3 2020, up from $58.5 million in Q3 2019.
Glaucoma net sales amounted to $51.9 million, while Corneal Health net sales were $12.9 million in Q3 2020.
Gross margin was approximately 72%, and non-GAAP gross margin was approximately 85% in Q3 2020.
Operating expenses totaled $59.3 million, and non-GAAP operating expenses were $57.5 million in Q3 2020.
Revenue by Segment
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...